Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C48404
http://purl.obolibrary.org/obo/NCIT_C48404
|
|---|---|
| Preferred Name | Tandutinib |
| Definitions |
A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. |
|---|---|
| prefLabel | Tandutinib
|
| label | Tandutinib
|
| PDQ_Closed_Trial_Search_ID | 353146
|
| code | C48404
|
| Has_Target | |
| prefixIRI | NCIT:C48404
|
| in_subset |
See more
See less
|
| Display_Name | Tandutinib
|
| Preferred_Name | Tandutinib
|
| FDA_UNII_Code | E1IO3ICJ9A
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C31H42N6O4
|
| Maps_To | Tandutinib
|
| CAS_Registry | 387867-13-2
|
| NSC Number | 726292
|
| NCI_Drug_Dictionary_ID | 353146
|
| Legacy Concept Name | MLN518
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of some types of cancer. It may stop cancer cell growth by blocking certain enzymes. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 353146
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1143028
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |